Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.7K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

8.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting and reversing T-cell engager resistance.

Blood·2026
Same author

A DNA methylation-based algorithm for diagnosing rheumatoid arthritis.

Arthritis research & therapy·2025
Same author

Production of mRNA-Loaded Dendritic Cell Cancer Vaccines.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Tackling paper mills requires us to prevent future contamination and clean up the past - the case of the journal <i>Bioengineered</i>.

Bioengineered·2025
Same author

Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study.

Cancer immunology, immunotherapy : CII·2025
Same author

Nuclear mechano-confinement induces geometry-dependent HP1α condensate alterations.

Communications biology·2025

Related Experiment Video

Updated: Feb 16, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.7K

Human c-SRC kinase (CSK) overexpression makes T cells dummy.

Else Marit Inderberg1, Nadia Mensali1,2,3, Morten P Oksvold4,5

  • 1Section for Cellular Therapy, Department for Cancer Treatment, Oslo University Hospital-Radiumhospitalet, PO Box 4953, Nydalen, 0424, Oslo, Norway.

Cancer Immunology, Immunotherapy : CII
|December 18, 2017
PubMed
Summary

Engineered T cells (TCR) can fight tumors but may cause off-target effects. Overexpressing CSK creates "dummy T cells" that bind targets but lack effector functions, enabling safer TCR validation before therapy.

Keywords:
CSKImmunotherapyT-cell receptorTCRTCR signalling

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Experiment Videos

Last Updated: Feb 16, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.7K
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Area of Science:

  • Immunology
  • Cancer Therapy
  • Cellular Engineering

Background:

  • Adoptive cell therapy using T-cell receptor (TCR)-engineered T cells shows promise for cancer treatment.
  • TCRs target specific peptide-MHC (pMHC) complexes, but cross-reactivity and off-target effects pose significant safety risks.
  • Developing strategies to validate TCR safety before clinical application is crucial.

Purpose of the Study:

  • To investigate a novel method for validating the safety of TCR-engineered T cells.
  • To determine if blocking intracellular signaling downstream of TCR engagement can prevent T-cell effector functions without compromising target recognition.

Main Methods:

  • Overexpressed c-SRC kinase (CSK), a negative regulator of LCK, in T cells engineered with a therapeutic TCR.
  • Assessed the impact of CSK overexpression on TCR proximal signaling, ERK phosphorylation, and downstream effector functions (IL-2 release, degranulation, target cell killing).
  • Evaluated TCR expression, pMHC binding, and trogocytosis in CSK-overexpressing T cells.

Main Results:

  • CSK overexpression inhibited anti-CD3/anti-CD28-induced ERK phosphorylation but did not affect TCR proximal signaling.
  • CSK co-expression with a therapeutic TCR blocked pMHC-induced ERK phosphorylation and downstream effector functions, including target cell killing.
  • TCR expression, pMHC recognition, and trogocytosis remained unaffected, indicating preserved target binding.

Conclusions:

  • Co-expression of CSK with therapeutic TCRs creates
  • dummy T cells
  • that retain target recognition but are functionally inactivated.
  • This approach offers a promising safety validation strategy for TCR-engineered T cells prior to clinical use, mitigating risks associated with off-target effects.